Evidence map›Paper›PMID 41514864›Full record

ArticleBiology2025

Regulation of

Chiachen Chen, Siyuan Cheng, Xiuping Yu, Yisheng Lee, Michael S Lan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chiachen ChenDepartment of Genetics, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Siyuan ChengDepartment of Biochemistry & Molecular Biology, LSU Health Shreveport, Shreveport, LA 71103, USA.
Xiuping YuDepartment of Biochemistry & Molecular Biology, LSU Health Shreveport, Shreveport, LA 71103, USA.
Yisheng LeeForesee Pharmaceuticals, Newark, DE 19713, USA.
Michael S LanDepartment of Genetics, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.ORCID 0000-0003-4596-5677

Funding

Discovering adenosine kinase inhibitor targets in human neuroblastomaR21CA218764 · NCI · LSU HEALTH SCIENCES CENTER · PI LAN, MICHAEL S · 2018 to 2019
$344k
NCI NIH HHS R21CA218764
6 · The paper itself

Abstract

Neuroblastoma (NB), a pediatric cancer of sympatho-adrenal (SA) lineage, is marked by disrupted differentiation and cellular heterogeneity. INSM1, a zinc-finger transcription factor, is highly expressed in NB and developing SA tissues, where it regulates neuroendocrine differentiation, especially in chromaffin cells. We investigated INSM1's role in maintaining an undifferentiated, progenitor-like state in NB and its regulation via metabolic and epigenetic mechanisms. Transcriptomic profiling, promoter assays, and metabolic flux analysis revealed that INSM1 expression correlates with methionine cycle activity, particularly the S-adenosylmethionine (SAM)/S-adenosylhomocysteine (SAH) ratio. Disruption of SAM/SAH balance altered

Indexed as

5′-iodotubercidinINSM1methionine cycle signalingneuroblastomaneuroendocrine differentiationN-MycSAHSAMsympatho-adrenal lineage

Identifiers

PMID41514864
PMCPMC12784908

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.